Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) has issued an announcement.
JW Therapeutics announced that the National Medical Products Administration of China has accepted its post-marketing supplementary application for Carteyva®, which now uses an in-house produced lentiviral vector. This development is significant as it ensures a stable supply and reduces costs, enhancing the commercial value of Carteyva® and strengthening JW Therapeutics’ position in the competitive cell therapy market.
The most recent analyst rating on (HK:2126) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd is an independent and innovative biotechnology company focused on developing, manufacturing, and commercializing cell immunotherapy products. The company is known for its CAR-T cell immunotherapy product, Carteyva®, which is approved for multiple oncology indications in China.
Average Trading Volume: 4,988,280
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.94B
Learn more about 2126 stock on TipRanks’ Stock Analysis page.